On August 1, 2025, a UK Court of Appeal upheld the validity of Moderna’s European Patent No. 3,590,949 (“EP’949”) in a dispute with Pfizer ...

COVID-19 activity is rising in much of the country. Data shows overall respiratory virus spread is very low in the U.S.

Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...

The completion of this study could positively impact Pfizer and BioNTech’s stock performance, as successful results may lead to new vaccine offerings, enhancing their market position. This development ...

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates Entered into ...

Showing that his loyalty to his own anti-vax mentality is greater than his loyalty to President Donald Trump, Robert F. Kennedy Jr., the dangerous quack atop the Department of Health and Human ...

New members to the Access Advance patent pool and Harvard University coming under fire were also among the top talking points ...

Parents in the United States who want to vaccinate their young children against Covid-19 this fall may face a growing set of ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...

CureVac ( (CVAC)) has provided an announcement. On August 7, 2025, CureVac announced the resolution of U.S. patent litigation with Pfizer/BioNTech concerning mRNA-based COVID-19 vaccines. As part of ...

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...